Organon & Co. (NYSE:OGN) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have received an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.00.

A number of research firms recently weighed in on OGN. Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research report on Friday, May 2nd. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Morgan Stanley dropped their price target on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Finally, Piper Sandler cut their price target on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a report on Thursday, May 15th.

Organon & Co. Price Performance

Shares of OGN opened at $9.11 on Friday. The company has a debt-to-equity ratio of 16.49, a quick ratio of 1.15 and a current ratio of 1.67. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10. The firm has a 50-day simple moving average of $9.76 and a 200-day simple moving average of $11.95. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 3.38, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The company had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a return on equity of 182.69% and a net margin of 11.15%. The firm's revenue for the quarter was down .8% on a year-over-year basis. During the same period last year, the firm earned $1.12 EPS. On average, equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Friday, August 15th will be issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Organon & Co.'s dividend payout ratio (DPR) is currently 2.97%.

Institutional Trading of Organon & Co.

Several hedge funds and other institutional investors have recently made changes to their positions in OGN. Hanson & Doremus Investment Management acquired a new position in Organon & Co. during the second quarter worth about $26,000. Hantz Financial Services Inc. boosted its stake in shares of Organon & Co. by 293.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company's stock worth $26,000 after acquiring an additional 1,995 shares in the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Organon & Co. in the 1st quarter worth approximately $32,000. SouthState Corp increased its stake in Organon & Co. by 1,857.0% in the 2nd quarter. SouthState Corp now owns 3,914 shares of the company's stock valued at $38,000 after purchasing an additional 3,714 shares in the last quarter. Finally, GeoWealth Management LLC acquired a new position in Organon & Co. during the fourth quarter worth $41,000. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.